MRSH Marsh McLennan
Elite fee franchise with steady 26% ROE, but the market already pays a full price for it.
The story
Marsh McLennan is the largest global insurance broker and consultant, an asset-light fee franchise that earns commissions rather than taking underwriting risk, so its returns are structurally high and far less cyclical than a carrier's. The trailing 26% ROE sits below the roughly 28-30% of 2022-2023, pulled down by the debt-funded McGriff acquisition, added goodwill and integration costs. Book equity is small next to earnings power because of decades of buybacks and acquired intangibles. The cycle risk is a softening P&C pricing market and slower organic growth (now mid-single digits after 7-9%), not credit losses.
A 26% normalized ROE fits a broker with a long, stable record of 25-30% returns and assumes no rebound to the prior peak, while mean reversion is modest because it holds no underwriting balance sheet. Book grows only about 7% because roughly 75-80% of earnings go out as dividends and buybacks, and terminal growth of 4.5% stays below the 5.15% risk-free rate. A beta of 0.85 (cost of equity about 9.0%) sits just under the 0.9 anchor, reflecting recurring fee revenue; because RI anchors on a buyback-shrunk book, it will undervalue this franchise versus the market, which prices earnings power rather than equity.
Value drivers
| Return on equity (normalized) | 25.0% |
| Book-value growth (Y1) | 7.0% |
| Terminal book growth | 4.5% |
| Beta | 0.85 |
| Failure probability | 1.0% |
| Cost of equity | 9.0% |
Valuation bridge
| PV of excess returns | 11.64B |
| PV of terminal excess | 5.00B |
| Equity value | 31.43B |
| ÷ shares → per share | $65.86 |
Projected excess returns on equity
| Yr | Book equity | ROE | Excess return | PV |
|---|---|---|---|---|
| 1 | 15.10B | 25.0% | 2.42B | 2.22B |
| 2 | 16.16B | 23.4% | 2.34B | 1.97B |
| 3 | 17.24B | 21.9% | 2.23B | 1.72B |
| 4 | 18.35B | 20.3% | 2.08B | 1.48B |
| 5 | 19.49B | 18.8% | 1.91B | 1.24B |
| 6 | 20.63B | 17.2% | 1.70B | 1.01B |
| 7 | 21.79B | 15.6% | 1.45B | 797.35M |
| 8 | 22.95B | 14.1% | 1.17B | 590.78M |
| 9 | 24.11B | 12.5% | 858.17M | 396.07M |
| 10 | 25.27B | 11.0% | 505.33M | 214.02M |
Key risks
- Softening commercial P&C rates and lower fiduciary interest income compress organic growth and margins
- McGriff integration and acquired goodwill dilute ROE and raise leverage
- Oliver Wyman and Mercer consulting are cyclical, and AI-driven disintermediation could erode broker commissions over time
Catalysts
- McGriff cost synergies and middle-market cross-selling lift margins toward 26%+
- Continued buybacks and deleveraging restore ROE toward the 28-30% range